What Is Mirogabalin? A Full Analysis of the Clinical Advantages and Quality Control of the New-Generation α2δ Ligand for Neuropathic Pain

1. Mirogabalin: A More Selective α2δ Ligand Than Pregabalin

Mirogabalin (CAS: 1138245-13-2; besylate salt CAS: 1138245-21-2), development code DS-5565, belongs to the gabapentinoid class with the molecular formula C12H19NO2. It is clinically used mainly for the treatment of peripheral neuropathic pain such as diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN).

Mirogabalin

Its main mechanism of action is high-affinity binding to the α2δ-1 subunit of voltage-gated calcium channels (VGCC), inhibiting calcium influx, thereby reducing the excessive release of excitatory neurotransmitters such as glutamate, lowering abnormal neuronal firing under pain sensitization, and exerting an analgesic effect. Compared with pregabalin, mirogabalin has higher selectivity for the α2δ-1 subunit and relatively weaker action on the α2δ-2 subunit. Since the α2δ-2 subunit is considered closely related to central nervous system adverse reactions such as dizziness and somnolence, this selectivity difference helps maintain analgesic efficacy while reducing related adverse reactions. In addition, mirogabalin has a longer dissociation half-life after binding to the receptor, giving it certain advantages in duration of efficacy and tolerability.

2. Drug Overview and Market Background: Filling the Gap in Neuropathic Pain Treatment in China

Diabetic peripheral neuropathic pain (DPNP) is the most common chronic complication-related pain type in diabetes; patients often present with persistent burning, tingling, and electric shock-like pain, severely affecting sleep quality and daily function.

From an epidemiological perspective, China currently has about 140 million diabetic patients, with an adult prevalence of 12.8%. On this basis, the domestic incidence of diabetic peripheral neuropathy (DPN) is about 21.8%, of which 57.2% of patients further progress to DPNP, giving an estimated total of about 22 million DPNP patients in China. However, the treatment rate for this disease has long been below 20%, and historically the targeted drugs available were extremely limited, leaving a huge unmet clinical need.

It is against this background that mirogabalin besylate tablets (trade name: TARLIGE®) were approved for marketing by the National Medical Products Administration (NMPA) on June 28, 2024, becoming China's first innovative drug specifically approved for adult DPNP. In November of the same year, the drug was included in the 2024 National Reimbursement Drug List through negotiation, limited to adult DPNP patients, further improving clinical accessibility.

Mirogabalin was independently developed by Daiichi Sankyo of Japan, first approved in Japan in January 2019 with indications covering peripheral neuropathic pain (including DPNP and postherpetic neuralgia PHN), and further expanded to central neuropathic pain (CNP) in March 2022. Global sales have continued to grow since launch, with cumulative sales of JPY 142.9 billion (approximately USD 1 billion) from 2019 to 2023 and global sales of JPY 45.7 billion in 2023 alone, demonstrating significant commercial value and clinical recognition.

3. Impurity Profile Analysis: Challenges in Controlling Chiral Purity and Structure-Specific Impurities

The molecular structure of mirogabalin contains three chiral centers (1R,5S,6S), and its synthetic route involves the stereoselective construction of a bicyclo[3.2.0]heptane skeleton. This structural feature determines the complexity of its impurity profile and is also the core difficulty in the quality control of the API and generics.

Image source: AI-generated

Key Analytical Method Points

Chiral impurities are usually detected by chiral-column HPLC, requiring specially developed separation methods to distinguish enantiomer peaks; lactam impurities, owing to large polarity differences, require dedicated optimization of mobile phase selection and gradient programs. Comprehensive characterization requires integrated evaluation using ¹H NMR, ¹³C NMR, IR, high-resolution mass spectrometry (HRMS), and HPLC purity.

For generic applicants, conducting risk assessment of potential genotoxic impurities in accordance with ICH M7 while meeting the impurity identification and limit reporting thresholds in ICH Q3A is a key compliance requirement for registration.

4. Generic Development Landscape: Patent Cliff Window and Intensifying First-Filer Competition

The compound patent expires in 2028, meaning the generic market window has entered its countdown, and major domestic generic companies have already begun actively preparing first-filer applications. Currently, companies such as Yuandong Biotech, Qilu Pharmaceutical, and Chia Tai Tianqing have all submitted generic applications for mirogabalin besylate tablets, with market competition becoming increasingly intense.

For generic R&D institutions, high-purity reference standards (including API reference standards and various impurity reference standards) are indispensable basic materials for bioequivalence studies, analytical method validation (AMV), and stability testing; the supplier's qualifications and traceability system directly affect the quality credibility of the application materials.

As a certified reference material producer in China with dual CNAS and ANAB ISO 17034 accreditation, CATO can provide systematic support for the full-lifecycle quality control of mirogabalin, covering API reference standards, known impurity reference standards, and custom synthesis services. All products come with complete identification data (NMR, MS, HPLC purity) and standardized COA, meeting the filing requirements of ICH, FDA, CDE, and other regulatory systems.

CATO Supports the Efficient Development of Mirogabalin Generics

In the "race" of generic drug development, conquering the impurity analysis challenge first is seizing the advantage in filing.

For the complex chiral structure and diverse impurity profile of mirogabalin, CATO has built a complete reference standard matrix for you. We now have in stock a series of reference materials including the mirogabalin API, lactam intermediates, and multiple process-related impurities (such as Impurities 1, 2, 3, 4, 5, 6, etc.). All products have been verified by high-resolution mass spectrometry (HRMS), nuclear magnetic resonance (NMR), and HPLC purity, ensuring the accuracy and compliance of your application data.